)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Newbury Pharmaceuticals
Newbury Pharmaceuticals (NEWBRY) investor relations material
Newbury Pharmaceuticals Q4 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 25/26 earnings summary28 Oct, 2026
Executive summary
FY 2025/26 net revenue rose to SEK 42.7m from SEK 31.6m; EBITDA remained negative at SEK -18.3m versus SEK -16.3m.
Q4 revenue increased to SEK 13.6m from SEK 5.9m, while quarterly EBITDA improved to SEK -5.1m from SEK -5.9m.
Continued portfolio expansion and planned launches supported growth, but lower margins, negative operating cash flow and funding needs remain key challenges.
Financial highlights
FY net revenue was SEK 42.685m versus SEK 31.573m; Q4 revenue was SEK 13.578m versus SEK 5.915m.
FY EBIT was SEK -20.660m versus SEK -21.966m; result before tax was SEK -22.919m versus SEK -23.603m.
FY EBITDA was SEK -18.309m versus SEK -16.299m; Q4 EBITDA improved to SEK -5.141m from SEK -5.876m.
FY operating cash flow was SEK -19.680m versus SEK -12.370m; year-end cash was SEK 9.344m versus SEK 14.562m.
Outlook and guidance
Management’s primary goal is EBITDA breakeven, with portfolio prioritization, cost management and commercial execution supporting that objective.
Target remains more than 30 Nordic product launches by Dec 2026; 29 products were launched at year-end.
Negative operating cash flow is expected to continue in FY 2026/27; funding measures may be needed, with management assessing they can be executed during the year.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Newbury Pharmaceuticals
- Q3 revenue rose 34% year-over-year, with narrowed losses and expanded financing.NEWBRY
Q3 25/26 - Portfolio growth and Nordic sales surge set the stage for major launches and recovery in 2026.NEWBRYLife Science Conference 2026
- Interim revenue up 6% year-over-year, with new launches and extended financing supporting growth.NEWBRYQ2 25/26
- Revenue up 79% year-over-year, but losses and cash outflow increased amid expansion.NEWBRYQ1 25/26
- Revenue and earnings declined sharply year-over-year, with cash flow and liquidity under pressure.NEWBRYQ4 24/25
- Q3 revenue up 382% year-over-year, with narrowed losses and strong Nordic market momentum.NEWBRYQ3 24/25
- Record Q4 sales and first positive EBITDA achieved, driven by strong Nordic and international growth.NEWBRYQ4 23/24
- Interim revenue doubled year-over-year, with strong Nordic sales and improved cash position.NEWBRYQ3 23/24
- Revenue growth and narrowed losses highlight progress, but funding needs remain.NEWBRYQ2 24/25
Next Newbury Pharmaceuticals earnings date
Q1 26/2720 Jan, 2027
Newbury Pharmaceuticals
Next Newbury Pharmaceuticals earnings date
Q1 26/2720 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Newbury Pharmaceuticals AB is a Sweden-based company specializing in specialty prescription drugs. The company's portfolio includes products across therapeutic areas such as oncology, rare diseases, and neurology. Newbury Pharmaceuticals primarily serves the Scandinavian market, focusing on developing both proprietary and licensed pharmaceutical products. The company is headquartered in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.